| Literature DB >> 27819379 |
Abstract
Entities:
Mesh:
Year: 2016 PMID: 27819379 PMCID: PMC5319461 DOI: 10.5935/abc.20160140
Source DB: PubMed Journal: Arq Bras Cardiol ISSN: 0066-782X Impact factor: 2.000
Declaration of potential conflict of interest of authors/collaborators of 7th Brazilian Guideline of Arterial Hypertension If the last three years the author/developer of the Guidelines:
| Names Membersof the Policy | Participated in clinical studies and / or experimental trials supported by pharmaceutical or equipment related to the guideline in question | Has spoken at events or activities sponsored by industry related to the guideline in question | It was (is) advisory board member or director of a pharmaceutical or equipment | Committees participated in completion of research sponsored by industry | Personal or institutional aid received from industry | Produced scientific papers in journals sponsored by industry | It shares theindustry |
|---|---|---|---|---|---|---|---|
| Alexandre Alessi | No | No | No | No | No | No | No |
| Ana Cristina Simões e Silva | No | No | No | No | No | No | No |
| Andrea Araujo Brandão | Novartis | Biolab, Daiichi Sankyo, Novartis, Servier | No | No | Biolab, Daiichi Sankyo, Novartis, Servier | Biolab, Novartis, Servier, SEM | No |
| Angela Maria Geraldo Pierin | No | No | No | No | No | No | No |
| Antonio Carlos Cordeiro Júnior | No | No | No | No | No | No | No |
| Armando da Rocha Nogueira | No | No | No | No | No | No | No |
| Audes Diógenes Feitosa | No | No | No | No | No | No | No |
| Carlos Alberto Machado | No | No | No | No | No | No | No |
| Carlos Eduardo Poli de Figueiredo | No | No | No | No | No | No | No |
| Celso Amodeo | Servier | No | Biolab | Servier | Ache, Servier, Merck Serona, AstraZeneca, Biolab | Novartis | No |
| Cibele Isaac Saad Rodrigues | No | No | No | No | No | No | No |
| Cláudia Lúcia de Moraes Forjaz | No | No | No | No | No | No | No |
| Fernando Antonio Almeida | No | No | No | No | No | No | No |
| Frida Liane Plavnik | No | No | No | No | No | No | No |
| Paulo César Veiga Jardim | No | Biolab - Servier - Novartis - Aché | No | No | Servier, Ministério da Ciência, CNPq | No | No |
| Deborah Malta | No | No | No | No | No | No | No |
| Décio Mion Júnior | No | No | No | No | No | No | No |
| Dilma do Socorro Moraes de Souza | No | No | No | No | No | No | No |
| Eduardo Barbosa Coelho | No | No | No | No | No | No | No |
| Eduardo Costa Duarte Barbosa | Novartis, Servier, MSD, Takeda, Amgen, AstraZeneca, Pfizer | No | No | No | Servier, Biolab | No | No |
| Elizabeth Muxfeldt | No | No | No | No | No | No | No |
| Emilton Lima Júnior | No | Biolab | No | No | No | No | No |
| Fernanda Consolim Colombo | Ache,Novartis | Daiichi Sankyo,Servier,Merck,Boehringer, Novartis | No | No | No | Libbs,Merck | No |
| Fernando Nobre | No | Novartis Biociências,Merck Soreno,SEM,Sanofi-Aventi,Libbs Farmacêutica | No | Novartis Biociências,Libbs Farmacêutica | Sanofi-Aventis,Libbs Farmacêutica | SEM,Novartis Biociências,Biolab,Torrent,Bayer,Libbs Farmacêutica | No |
| Flávio Antonio de Oliveira Borelli | No | Servier | No | No | No | No | No |
| Gil Fernando Salles | No | No | No | No | No | No | No |
| Gilson Soares Feitosa | No | No | No | No | No | No | No |
| Giovanio Vieira da Silva | No | No | No | No | No | No | No |
| Guido Bernardo Aranha Rosito | No | No | No | No | No | No | No |
| Heitor Moreno Júnior | No | No | No | No | No | No | No |
| Heno Ferreira Lopes | No | No | No | No | No | No | No |
| Isabel Cristina Britto Guimarães | No | No | No | No | No | No | No |
| Ivan Carlos Antonello | No | No | No | No | No | No | No |
| José Fernando Vilela Martim | No | No | No | No | No | No | No |
| José Marcio Ribeiro | No | Biolab,B Ingelheim,Pfizer | No | No | Servier | No | No |
| Juan Yugar Toledo | No | No | No | No | No | No | No |
| Leda Aparecida Daud Lotaif | No | No | No | No | No | No | No |
| Lilian Soares da Costa | No | No | No | No | No | No | No |
| Lucélia Batista Neves Cunha Magalhaes | No | No | No | No | No | No | No |
| Luciano Ferreira Drager | No | No | No | No | No | No | No |
| Luis Cuadrado Martins | No | No | No | No | No | No | No |
| Luiz Aparecido Bortolotto | Novartis | Servier, Biolab, Novartis | No | No | No | Biolab, Novartis, Servier, Baldacci | No |
| Luiz Carlos Bodanese | Sanofi, GSK, Roche | Sanofi, Novartis, Boehringer | No | Servier, Sanofi, ANGEM | Safoni, ANGEM, GSK | Pfizer | No |
| Luiz Cesar Nazario Scala | No | No | No | No | No | No | No |
| Marcia Maria Godoy Gowdak | No | No | No | No | No | No | No |
| Marcia Regina Simas Torres Klein | No | No | No | No | No | No | No |
| Marco Antonio Mota Gomes | Novartis, AstraZeneca, Biolab, Daiichi Sankyo,Takeda, Torrent, Libbs, Pfizer, Janssen, Cardios, Omron | No | No | No | No | No | No |
| Marcus Vinícius Bolívar Malachias | No | Biolab, Chiesi, Medley-Sanofi, Novartis, Pfizer | No | No | No | Biolab, Boehringer-Ingelheim, Novartis | No |
| Maria Eliane Magalhães | AstraZeneca, Novartis, Sanofi-Aventis, Daiichi Sankyo | AstraZeneca, Pfizer, Sanofi-Aventis, MSD, Chiesi | No | No | AstraZeneca, Pfizer, MSD, Novartis | No | No |
| Maria Regina Torloni | No | No | No | No | No | No | No |
| Maria Rita de Figueiredo Lemos Bortolotto | No | No | No | No | No | No | No |
| Mário Fritsch Toros Neves | Novartis, Servier, AstraZeneca, Pfizer, Sanofi, Libbs | No | Novartis, Servier | No | No | No | No |
| Miguel Gus | No | No | No | No | No | No | No |
| Nelson Sass | No | No | No | No | No | No | No |
| Osni Moreira Filho | No | No | No | No | Biolab, Pfizer, Novartis | EMS | No |
| Oswaldo Passarelli Júnior | Biolab, Novartis, Daiichi Sankyo | ||||||
| Paulo Koch Nogueira | No | No | No | No | No | No | No |
| Roberto Dischinger Miranda | Aché, Astra Zeneca, Bayer, Biolab, Boeringher Ingelheim, MSD, Novartis, Pfizer | No | Bayer, Novartis, Pfizer | No | No | No | No |
| Roberto Jorge da Silva Franco | No | No | No | No | No | No | No |
| Rogério Baumgratz de Paula | No | No | No | No | No | No | No |
| Rui Manuel dos Santos Póvoa | No | No | No | No | No | No | No |
| Sandra Fuchs | No | No | No | No | No | No | No |
| Sebastião Ferreira Filho | No | No | No | No | No | No | No |
| Sergio Kaiser | Bristol-Myers-Squibb, Novaquimica, Abbott | No | No | No | No | No | No |
| Thiago de Souza Veiga Jardim | Novartis, Astra Zeneca | Biolab, Daiichi Sankyo, Novartis, Astra Zeneca, Servier | Daiichi Sankyo, Servier | Daiichi Sankyo | |||
| Vera Koch | No | No | No | No | No | No | No |
| Victor Matsudo | No | No | No | Instituto Actigraph | No | No | No |
| Weimar Kunz Sebba Barroso de Souza | Amgen, AstraZeneca, Bayer, Boehringer, Jonhson & Johnson, Libbs, Lilly, Merck Sharp Dhome, Novartis, Pfizer, Roche, Sanofi Aventis, Daiichi Sankyo, Torrent | AstraZeneca, Biolab, Boehringer, Lilly, Servier, Torrent | No | No | No | No | No |
| Wille Oigman Cobrei | Libbs | No | No | No | No | No | No |
| Grades of recommendation: |
| Class I: Conditions to which there is conclusive evidence or at least general consensus concerning the safety and usefulness/efficacy of the intervention; |
| Class II: Conditions to which there is conflicting evidence and/or disagreement of opinion concerning the safety and usefulness/efficacy of the intervention; |
| Class IIa: Evidence/opinion in favor of the intervention. Most experts agree; |
| Class IIb: Less well-established safety and usefulness/efficacy, without predominance of favorable opinions on the intervention; |
| Class III: Conditions to which there is evidence and/or consensus that the intervention is not useful/effective, and, in some cases, even harmful. |
| Levels of evidence: |
| Level A: Data derived from multiple consistent randomized controlled clinical trials, and/or a robust meta-analysis of randomized clinical trials; |
| Level B: Data derived from a less robust meta-analysis, one single randomized trial or non- randomized trials (observational); |
| Level C: Data derived from consensual expert opinion. |
| We hope the concepts expressed in this guideline can be widely spread to a better and more comprehensive care of individuals with arterial hypertension. |
Abbreviations of the Brazilian Guideline of AH
| ABI | Ankle-brachial index | ||
| ABPM | Ambulatory blood pressure monitoring | IDF | International Diabetes Federation |
| AC | Abdominal circumference | IGF-1 | Insulin-like growth factor 1 |
| ACC | American College of Cardiology | IHD | Ischemic heart diseases |
| ACEI | Angiotensin-converting-enzyme inhibitor | IMT | Intima-media thickness |
| ACTH | Adrenocorticotropin | IPEMs | State Departments of Weights and Measures |
| AH | Arterial hypertension | ISH | Isolated systolic hypertension |
| AHA | American Heart Association | IV | Intravenous |
| AHI | Apnea-hypopnea index | LVH | Left ventricular hypertrophy |
| AKI | Acute kidney injury | LVMI | Left ventricular mass index |
| Aldo | Aldosterone | MH | Masked hypertension |
| AMI | Acute myocardial infarction | MI | Myocardial infarction |
| APA | Aldosterone-producing adenoma | MIBG | Metaiodobenzylguanidine |
| APE | Acute pulmonary edema | MRI | Magnetic resonance imaging |
| ARB | Angiotensin II receptor blocker | MS | Metabolic syndrome |
| BB | Beta-blocker | NKF | National Kidney Foundation |
| BMI | Body mass index | NPT | Non-pharmacological treatment |
| BP | Blood pressure | OSAHS | |
| CAD | Coronary artery disease | PAD | Peripheral arterial disease |
| CAH | Chronic arterial hypertension | PE | Preeclampsia |
| CbVD | Cerebrovascular diseases | PH | Prehypertension |
| CCB | Calcium-channel blocker | PHA | Primary hyperaldosteronism |
| CDC | Centers for Disease Control and Prevention | PHEO | Pheochromocytoma |
| CHF | Congestive heart failure | PNS | Brazilian National Health Survey |
| CKD | Chronic kidney disease | POF | Survey on Family Income |
| COPD | Chronic obstructive pulmonary disease | PP | Pulse pressure |
| CPAP | Continuous positive airway pressure | PRA | Plasma renin activity |
| CrCl | Creatinine clearance | PSNS | Parasympathetic nervous system |
| CS | Cushing’s syndrome | PTH | Parathormone |
| CT | Computed tomography | PVR | Peripheral vascular resistance |
| CV | Cardiovascular | PWV | Pulse wave velocity |
| CVD | Cardiovascular disease | RAAS | Renin-angiotensin-aldosterone system |
| CVRF | Cardiovascular risk factor | RAH | Resistant arterial hypertension |
| DAH | Diastolic arterial hypertension | RBMLQ | Brazilian Legal Metrology and Quality Network |
| DBP | Diastolic blood pressure | RF | Risk factor |
| DHA | Docosahexaenoic acid | RVAH | Renovascular arterial hypertension |
| DIU | Diuretic | SAH | Systemic arterial hypertension |
| DM | Diabetes mellitus | SBP | Systolic blood pressure |
| EPA | Eicosapentaenoic acid | SNP | Sodium nitroprusside |
| GFR | Glomerular filtration rate | SNS | Sympathetic nervous system |
| GH | Growth hormone | SUS | Brazilian Unified Health Care System |
| GRS | Global Risk Score | TC | Total cholesterol |
| HbA1c | Glycated hemoglobin | TIA | Transient ischemic attack |
| HBPM | Home blood pressure monitoring | TOD | Target-organ damage |
| HC | Hypertensive crisis | TSH | Thyroid stimulating hormone |
| HD | Hypertensive diseases | UACR | Urine albumin/creatinine ratio |
| HDL-C | High-density lipoprotein cholesterol | US | Ultrasonography |
| HE | Hypertensive emergency | VIGITEL | Surveillance for Risk Factors and Protection Against Chronic Diseases via Telephone Inquiry |
| HF | Heart failure | WCE | White-coat effect |
| HR | Heart rate | WCH | White-coat hypertension |